Ivoclar Vivadent files ITC complaint against Dentsply

Schaan, Liechtenstein – 20 February 2014

Ivoclar Vivadent (“Ivoclar”), the innovator and manufacturer of IPS e.max® products, announced today that it has filed a complaint with the U.S. International Trade Commission against Dentsply International and its affiliates. The ITC complaint requests both that Dentsply’s CeltraTM products be excluded from importation into the United States, and that the distribution and sale of any such domestic inventories be stopped. The complaint asserts that Dentsply’s CeltraTM products infringe U.S. Patent Nos. 8,047,021 and 8,444,756, two of Ivoclar’s U.S. patents protecting its lithium-silicate technology. Ivoclar’s ITC complaint is related to a pending October 2013 lawsuit that Ivoclar filed against Dentsply in the United States District Court for the District of Delaware, which also asserted that Dentsply’s CeltraTM products infringed four Ivoclar patents pertaining to its lithium-silicate technology. Ivoclar Vivadent considers its lithium silicate technology and the patents protecting this technology to be very valuable and it will remain resolute and active in vigorously enforcing its patents in this area.

About Ivoclar Vivadent
Ivoclar Vivadent, headquartered in Schaan, Liechtenstein, is one of the world's leading manufacturers of innovative material systems for high-quality dental applications. The company's success is based on a comprehensive portfolio of products and systems, strong research and development capabilities and a clear commitment to training and further education. The company has wholly owned subsidiaries in 24 countries, and it employs over 3,000 people worldwide. More information about Ivoclar Vivadent is available at www.ivoclarvivadent.com.